Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29852043

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2018 Sep 1
First author
Joensuu H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2019 Jan 1;5(1):118. doi: 10.1001/jamaoncol.2018.5739.
    note
    Source null
    related pmid
    30520954
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2019 Jan 1;5(1):117-118. doi: 10.1001/jamaoncol.2018.5730.
    note
    Source null
    related pmid
    30520963
    relationship
    Comment in

Authors and identifiers

  1. name
    Joensuu H
    type
    Author
  2. name
    Fraser J
    type
    Author
  3. name
    Wildiers H
    type
    Author
  4. name
    Huovinen R
    type
    Author
  5. name
    Auvinen P
    type
    Author
  6. name
    Utriainen M
    type
    Author
  7. name
    Nyandoto P
    type
    Author
  8. name
    Villman KK
    type
    Author
  9. name
    Halonen P
    type
    Author
  10. name
    Granstam-Björneklett H
    type
    Author
  11. name
    Lundgren L
    type
    Author
  12. name
    Sailas L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Joensuu H
    type
    Author
  2. name
    Fraser J
    type
    Author
  3. name
    Wildiers H
    type
    Author
  4. name
    Huovinen R
    type
    Author
  5. name
    Auvinen P
    type
    Author
  6. name
    Utriainen M
    type
    Author
  7. name
    Nyandoto P
    type
    Author
  8. name
    Villman KK
    type
    Author
  9. name
    Halonen P
    type
    Author
  10. name
    Granstam-Björneklett H
    type
    Author
  11. name
    Lundgren L
    type
    Author
  12. name
    Sailas L
    type
    Author
bibliography ids
  1. nci-bib-ed827a7bb043fab30291d91c
book metadata
content sha256
fdecdc3d61d8bd1fbbc33fd7f3f90e8f7570445e7df7951f564325af20166a79
document type
citation
dois
  1. 10.1001/jamaoncol.2018.1380
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:29852043
immutable id
pubmed:29852043@fdecdc3d61d8bd1fbbc33fd7f3f90e8f7570445e7df7951f564325af20166a79
journal
abbreviation
JAMA Oncol
issn electronic
2374-2445
issn print
2374-2437
issue
9
name
JAMA oncology
nlm unique id
101652861
pages
1199-1206
volume
4
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2019 Jan 1;5(1):118. doi: 10.1001/jamaoncol.2018.5739.
    note
    Source null
    related pmid
    30520954
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2019 Jan 1;5(1):117-118. doi: 10.1001/jamaoncol.2018.5730.
    note
    Source null
    related pmid
    30520963
    relationship
    Comment in
outcomes validated
false
pmid
29852043
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
55637a20785857ae20e3fa2d25eccd221a784cce416fbd7de788f70beef0ee7e
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Sep 1
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29852043/
title
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Preserved source evidence · Not medical advice